tirzepatide study A 3-year of in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 Tirzepatide after intensive lifestyle intervention
Description
Semaglutide also slows down the process of digestion, so food stays in the stomach for longer and sugar enters the bloodstream more gradually
occasionally, the time of reaction onset occurred more than 1 year later
The majority of patients will have circulating volume depletion or SIAD
- Tirzepatide Similar to semaglutide, tirzepatide is a GLP-1 receptor agonist but is also a peptide called glucose-dependent insulinotropic polypeptide
Nutrients 2021;13:942
M., Freriksen J
